Alois Alzheimer's microscope and childhood home (Eli Lilly)
Failure, faith and $8 billion: How Lilly's amyloid conviction brought it to the brink of Alzheimer's approval
(This story was originally published in February 2024, and is being re-run following the approval of donanemab.)
Twenty-nine years ago, Eli Lilly bought …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
